COMP <GO>
PCVX vs ABBV // RSI-14 & 200D SMA MOMENTUM
Vaxcyte Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PCVX 4
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $62.03 (-0.93%) • MKT CAP: $9.85B
rsi-technicals
48.8
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 29.00% | -56.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 3.47% | -10.26 | ABBV | /fcf-yield <GO> |
| Operating Margin | -33.50% | 24.60% | -58.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 8.60% | +11.20 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 5.33 | +12.78 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | PCVX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 48.8 | 72.8 | -23.97 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 113.1x | -90.10 | PCVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.85B | $513.86B | -$504.01B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | ABBV REV | PCVX GROSS % | ABBV GROSS % | PCVX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$669.3M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$475.1M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$296.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
ABBV // BETA 1.15